Last reviewed · How we verify
RO5126766
At a glance
| Generic name | RO5126766 |
|---|---|
| Also known as | (CH5126766) |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Trial of Defactinib and VS-6766. (PHASE1)
- Phase I Trial of VS-6766 Alone and in Combination With Everolimus (PHASE1)
- Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma (EARLY_PHASE1)
- Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma (PHASE2)
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (PHASE2)
- RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer (PHASE1)
- A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO5126766 CI brief — competitive landscape report
- RO5126766 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI